1 tyrosine is catalyzed through a series of five enzymatic reactions. Disturbed tyrosine metabolism 2 has been implicated in several types of disease such as Huntington's disease 15 and esophageal 3 cancer 16, 17 . Previously reported. patients with hereditary tyrosinemia are more likely to develop 4 HCC 18, 19 . In patients with HCC, an upregulation of serum tyrosine has been recorded 20,21 , 5 suggesting a deregulated tyrosine metabolism in HCC. However, to date, there is a lack of 6 systematic study to profile the state of tyrosine catabolic enzymes and molecular impacts of 7 alteration in tyrosine catabolism in HCC development. 8 As previously reported, the frequent deletion of 16q22 and aberrant methylation led to the 9 downregulation of the first tyrosine catabolic enzyme TAT (tyrosine aminotransferase) 22 .
10 Functional analyses showed that TAT harbored proapoptotic effect and that TAT suppression 11 could promote liver tumorigenesis 22 . Glutathione S-transferases (GSTs) are a family of phase II 12 isoenzymes that detoxify toxicant to lower toxic 23 and its dysfunction has been found to be closely 13 related with response to chemotherapy [24] [25] [26] . GSTZ1 belongs to the zeta class of GSTs and is the 14 fourth enzyme in tyrosine metabolism. Patients carrying GSTZ1 variants had an increased risk of 15 bladder cancer when exposed to trihalomethanes 27 . Furthermore, a computational-based 16 investigation suggested GSTZ1 might act as a protective factor in ovarian cancer 28 .
1 Discussion 2 We explored publicly available gene expression data sets and database to investigate the roles of 3 genes in the tyrosine degradation pathway in the development of HCC. Our results indicated that 4 all tyrosine catabolic genes decreased in HCC compared to normal liver tissues. Furthermore, we 5 found that these genes gradually decreased from normal liver through early HCC to late HCC. We 6 demonstrated that the fourth rate-limiting enzyme, GSTZ1 expression significantly reduced, either 7 in protein or mRNA level, in HCC (Figure 2A, Figure 4 ). Even though the tyrosine catabolic gene 8 expression remained unchanged at early stage HCC, they were significantly down-regulated in late 9 stage HCC ( Figure 2B ). We also found that TAT, HGD and GSTZ1 expression levels positively 16 GSTZ1, which is expressed in both hepatic cytosol and mitochondria, has shown to be oxidative 17 stress-related 28 . High levels of GSTZ1 expression conferred resistance to the effect of anti-cancer 18 therapy of dichloroacetate in hepatocellular carcinoma cell lines by an independent mechanism to 19 tyrosine metabolism 47, 48 . We decided to further study the roles of GSTZ1 in HCC development by 20 exploring a public dataset where GSTZ1 were overexpressed in HCC cell line Huh7. We found 21 that with the expression of GSTZ1, there was positive enrichment of Biological Oxidations ( Figure   22 5, Supplementary Figure S2 ). Generally, cell generates ATP through oxidative phosphorylation 23 and produces ROS as a byproduct. Cancer cells have a higher tolerance for ROS and it is known 1 that low doses of ROS can stimulate growth in various types of cancer 11 . However, unbalanced 2 increase in ROS level can induce cancer cell cycle arrest, senescence and apoptosis 11 . Here, it is 3 appealing to assume that HCC can reprogram its tyrosine metabolism to maintain ROS balance as 4 a growth strategy. Additionally, we detected an overall enrichment in metabolism of proteins and 5 lipids pathways and decrease in glycolysis genes following GSTZ1 expression ( Figure 5 ). Liver is 6 a dynamic organ which constantly undergoes metabolic shift. Cancer cells, including HCC, usually 7 switch to aerobic glycolysis to maximize energy usage and further fuel growth 2 . Since 8 overexpression of GSTZ1 led to downregulation of several glycolysis genes, we consider it 9 possible that the suppression of tyrosine catabolism can be a mechanism by which HCC switch to 10 aerobic glycolysis during cancer progression. 11 The downregulation of other genes in the tyrosine catabolic pathways have not been linked to 12 changes in DNA. Thus, we reason that the downregulation of HPD, HGD, GSTZ1 and FAH might 13 be dependent or independent of the downregulation of TAT. We found that four out of five genes 14 were predicted to be regulated by miR-539, miR-661. Noticeably, investigation of TCGA-LIHC 15 dataset showed that miR-539 significantly increased in HCC compared to normal skin and that the 16 miR-539 level inversely correlated with expression of TAT, GSTZ1, HPD, FAH (Supplementary 17 Figure S4 ). Here, our analyses showed that expression of two of these microRNAs positively 18 correlated with overall survival in HCC patients ( Figure 6B ). As previously reported, miR-539 19 was usually downregulated and acted as tumor suppressors in various tumor types 49,50 . In HCC, 20 miR-539 was also demonstrated to suppress HCC development in vitro by targeting FSCN1 and 21 suppressing apoptosis 51,52 . Here, our findings suggested that on miR-539 might be a tumor 22 promoter in contrast to previous experimental studies. On the other hand, prior studies showed that 23 miR-661 was a tumor promoter in non-small cell lung cancer, colon cancer and ovarian cancer 53-1 55 . However, the roles of miR-661 in HCC development has not been investigated. Taken together, 2 we speculate that miR-539 and miR-661 can be potential regulators of tyrosine catabolic genes 3 and whether these regulation lead to HCC development need to be validated by functional studies.
4 Tyrosine metabolism is an important process that is often dysregulated in various diseases 5 including cancers and chronic disorders 56 . Tyrosinemia type I patients have a higher risk of 6 developing HCC 56 . The reasons for the high incidence of HCC are unknown but it has been 7 suggested that it may be caused by accumulated metabolites such as fumarylacetoacetate (FAA) 8 and maleylacetoacetate (MAA) 56 . A metabolomics study on esophageal cancer (EC) showed that 9 tyrosine decreased in serum of patients with EC compared with healthy control 57,58 . There has been 10 little evidence on how tyrosine metabolism might contribute to cancer development even though 11 changes in expression of some tyrosine metabolic genes have been reported in HCC patients 22,59 .
12 To summarize, our findings from the integrative databases and comprehensive analysis of this 13 study demonstrated the downregulation of tyrosine catabolic genes and their prognostic value in 14 HCC. We provided evidence on how suppressing these genes can benefit HCC development and 15 that tyrosine catabolism is a novel pathway through which HCC reprogram its metabolism. Finally, 16 we provided evidence suggesting that microRNAs can regulate the expression of tyrosine catabolic 17 genes and might be a potential prognostic biomarker for HCC. However, more investigations need 18 to be applied to fully reveal the role of tyrosine catabolism in HCC for further translational study. 19 We further discovered that the expression of GSTZ1, the fourth rate limiting enzyme in tyrosine 20 catabolism, regulates glycolytic gene expression. We provided evidence to support that tyrosine 21 catabolic genes can be regulated by microRNAs. Thus, we present here a novel function for 22 tyrosine catabolic genes in tumorigenesis and provide a previously unappreciated event by which 23 cancer cells reprogram tyrosine metabolism during cancer progression. 10 Gene expression analysis 11 The TCGA data was analysed by GEPIA 30 (http://gepia.cancer-pku.cn/). For the differential 12 expression analysis, the genes were log2(TPM + 1) transformed. One-way ANNOVA was used to 13 compute p value. Those with log2(TPM+1) > 1 and p < 0.01 were then considered differentially 14 expressed genes. Normal tissues are matched TCGA adjacent tissue and GTEx normal tissue.
15
16 Survival analysis 17 The overall survival curves of TAT, HPD, HGD, GSTZ1 and FAH were investigated using the 18 Kaplan-Meier method with the log-rank test. We set the high and low gene expression level 19 groups by the median value. The overall survival plot was obtained with the hazard ratios (HR) 20 and the 95% confidence interval information. The whole process was implemented using the 21 web-based tool GEPIA 30 .
1 The prognostic values of hsa-miR-539 and has-miR-661 in HCC were analyzed using Kaplan 2 Meier plotter (KM plotter) database 44 . In brief, the miRNAs were entered into the database, after 3 which survival plots were generated and hazard ratio, 95% confidence intervals, log rank P-value 4 were displayed on the webpage. The log-rank p value was calculated with <0.05 considered 5 statistically significant. Supplementary Table S1 ). TPM, transcript per 3 million. 
